‘Street Underestimates Jazz Pharma’s Cash-Flow’ Says This Analyst
HC Wainwright tweaked the price target on Jazz Pharmaceuticals plc (NASDAQ:JAZZ) to $204 with a reiterated Buy rating on slightly increased forward…
Pfizer, Global Blood Therapeutics In Advanced Talks For $5B Buyout Deal: Report
Pfizer Inc (NYSE: PFE) is reportedly in advanced talks to buy Global Blood Therapeutics Inc (NASDAQ: GBT) for about $5 billion, bolster its portfolio and pipeline.
Neurocrine Biosciences Shares Jump After Raising Ingrezza Sales Guidance
Tucked in its Q2 earning release, Neurocrine Biosciences Inc (NASDAQ:NBIX) said that in August, the Phase 2a study of NBI-827104…
Voyager Therapeutics Prioritizes Pipeline With Cash Runway Into 2024
Voyager Therapeutics Inc (NASDAQ:VYGR) unveiled its prioritized therapeutic pipeline focusing on tau antibody for Alzheimer’s disease and gene therapies for GBA1…
Akebia’s Anemia Drug Disappoints In Mid-Stage COVID-19 Study
Akebia Therapeutics Inc (NASDAQ:AKBA) announced initial findings from an investigator-sponsored study evaluating vadadustat for Acute Respiratory Distress Syndrome (ARDS) with COVID-19…
Kazia Therapeutics Shares Jump On Interim Data From Paxalisib Combo Study In Brain Metastases
Kazia Therapeutics Limited (NASDAQ:KZIA) announced the presentation of new data from an ongoing phase 1 trial of paxalisib in combination with…
uardant Health Announces New Data From Portfolio Of Blood Tests And GuardantINFORM Real-World Clinical-Genomic Platform At IASLC 2022 World Conference On Lung Cancer
Presentations to highlight role of liquid biopsy tests and real-world data in identifying resistance mechanisms to therapy, demonstrating impact of specific mutations on treatment efficacy, and informing therapeutic
FDA Asks For Additional Study For Acadia’s Pimavanserin In Alzheimer’s-Associated Delusions
The FDA has issued a Complete Response Letter (CRL) to Acadia Pharmaceuticals Inc (NASDAQ:ACAD) regarding its supplemental marketing application for pimavanserin in…
AstraZeneca Announced Calquence Tablet Formulation Approved in the US Across Current Indications
AstraZeneca's new tablet formulation of Calquence (acalabrutinib) has been approved in the US for all current indications, including adult patients with chronic lymphocytic leukaemia (CLL), small lymphocytic lymphoma (SLL) and for patients with relapsed or refractory mantle cell lymphoma (MCL), which is approved under accelerated approval based on overall response rate.
Genmab and BioNTech Expand Global Collaboration To Include Development Of Monospecific Antibody Candidates To Address Malignant Solid Tumors
Collaboration expands to include development of monospecific antibody candidates to address malignant solid tumors
Expanded collaboration leverages Genmab's proprietary HexaBody® technology platform to